GLPwatch
Papers (9189)
Page 30 of 154, ranked by citation count.
- Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
- GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
- Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
- Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
- The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
- Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
- Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
- Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
- Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
- PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.
- Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.
- Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
- Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway.
- Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
- Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats.
- Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
- Glucagon-like peptide-1 receptor agonist use in pregnancy: a review.
- Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
- Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.
- Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity.
- Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
- Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.
- Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.
- Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway.
- Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.
- A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction.
- Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide.
- Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
- Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
- Structural and functional diversity among agonist-bound states of the GLP-1 receptor.
- Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
- Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
- Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.
- Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
- Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
- Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
- Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice.
- Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
- Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats.
- GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.
- Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation.
- Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.
- GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
- The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia.
- Combined melatonin and exendin-4 therapy preserves renal ultrastructural integrity after ischemia-reperfusion injury in the male rat.
- Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
- Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
- Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway.
- An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
- Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.
- Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts.
- Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.
- FLOW trial stopped early due to evidence of renal protection with semaglutide.
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.